Most Promising Emerging Therapies for Pulmonary Fibrosis: Targeting Novel Pathways.

Additionally, there was a trend toward reduced mortality risk in patients treated with Nerandomilast 18 mg (hazard ratio 0.77, p = 0.06), although this did not reach statistical significance [ 40 ].

also in 111,027 other papers

Despite not meeting secondary endpoints (risk of acute exacerbation, hospitalization for respiratory cause, or death), a pooled analysis of the FIBRONEER trials showed that Nerandomilast 18 mg was associated with a nominally significant reduction in the risk of death by 43% overall, by 59% in patients without background therapy, and by 41% in patients with background Nintedanib [ 41 ].

also in 7,732 other papers

In the extension study up to 24 weeks, patients who continued on Zelasudil demonstrated stabilization of lung function, and those who switched from placebo to Zelasudil also showed a trend toward stabilization [ 79 ].

also in 53,322 other papers